Paul Rothman - Merck Independent Director
MRK Stock | USD 126.94 1.16 0.92% |
Director
Dr. Paul B. Rothman is Independent Director of the Company. Dr. Rothman oversees the Johns Hopkins Health System and school of medicine. A rheumatologist and molecular immunologist, he joined Johns Hopkins in July 2012 after having served as dean of the Carver College of Medicine at the University of Iowa and leader of its clinical practice plan since 2008. He previously served as head of internal medicine at the University of Iowa from 2004 until 2008. Prior to that, he was vice chairman for research and founding director of the Division of Pulmonary, Allergy and Critical Care Medicine at Columbia University College of Physicians and Surgeons, where he joined the faculty in 1986. Dr. Rothman is a 1980 Phi Beta Kappa graduate of the Massachusetts Institute of Technology and earned his medical degree from Yale University in 1984. He is a member of the American Society for Clinical Investigation and is a fellow of the American College of Physicians. He was elected to the council of Association of American Physicians as a fellow of the American Association for the Advancement of Sciences and as a member of the American Clinical and Climatological Association. since 2015.
Age | 63 |
Tenure | 9 years |
Address | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 |
Phone | 908 740 4000 |
Web | https://www.merck.com |
Merck Management Efficiency
The company has Return on Asset of 0.0264 % which means that on every $100 spent on assets, it made $0.0264 of profit. This is way below average. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to 0.01. The value of Return On Capital Employed is expected to slide to 0.04. At this time, Merck's Non Current Liabilities Total is quite stable compared to the past year. Non Current Liabilities Other is expected to rise to about 10.8 B this year, although the value of Total Current Liabilities will most likely fall to about 13.3 B.Similar Executives
Showing other executives | DIRECTOR Age | ||
Nancy Snyderman | Alkermes Plc | 66 | |
Michael Graves | Eagle Pharmaceuticals | 61 | |
Floyd Bloom | Alkermes Plc | 80 | |
Wendy Dixon | Alkermes Plc | 62 | |
Robert Breyer | Alkermes Plc | 73 | |
David Pernock | Eagle Pharmaceuticals | 63 | |
Anthony Quirk | Evotec SE ADR | N/A | |
Robert Glenning | Eagle Pharmaceuticals | 57 | |
Sander Flaum | Eagle Pharmaceuticals | 81 | |
Grainne Troute | Evotec SE ADR | N/A | |
Paul Mitchell | Alkermes Plc | 64 | |
Alain Schreiber | Eagle Pharmaceuticals | 58 | |
Lynda Reid | Evotec SE ADR | N/A | |
David Anstice | Alkermes Plc | 69 | |
Hamish Stevens | Evotec SE ADR | N/A | |
Steven Ratoff | Eagle Pharmaceuticals | 81 | |
Norah Barlow | Evotec SE ADR | N/A | |
Douglas Braunstein | Eagle Pharmaceuticals | 57 | |
Nancy Wysenski | Alkermes Plc | 60 | |
Richard Edlin | Eagle Pharmaceuticals | 57 | |
Edward Kay | Eagle Pharmaceuticals | N/A |
Management Performance
Return On Equity | 0.009 | ||||
Return On Asset | 0.0264 |
Merck Company Leadership Team
Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
Scot Ebbinghaus, VP Development | ||
Rochelle Lazarus, Independent Director | ||
Michael Rosenblatt, Executive Vice President Chief Medical Officer | ||
Paul Rothman, Independent Director | ||
Mary Coe, Independent Director | ||
Michael Fleming, Senior Vice President Chief Ethics and Compliance Officer | ||
Caroline Litchfield, Chief Financial Officer, Executive Vice President | ||
Mirian GraddickWeir, Executive Vice President - Human Resources | ||
Jannie Oosthuizen, Lead - Human Health U.S. | ||
Jennifer Mauer, VP Communications | ||
Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health | ||
Gregory Lubiniecki, VP Development | ||
Michael Klobuchar, Executive Vice President Chief Strategy Officer | ||
Patricia Russo, Independent Director | ||
David Williams, Executive Vice President Chief Information Chief Information and Digital Officer | ||
Franklin Clyburn, President, Human Health, Head of Human Health Commercial and Marketing | ||
Lisa LeCointeCephas, Senior Vice President Chief Ethics and Compliance Officer | ||
Robert Davis, Executive Vice President, Global Services, Chief Financial Officer | ||
Robert Kidder, Independent Director | ||
Thomas Cech, Independent Director | ||
William Harrison, Lead Independent Director | ||
Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources | ||
Jim Scholefield, Executive Vice President, Chief Information and Digital Officer | ||
Deepak Khanna, Lead - Human Health International | ||
Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division | ||
Gideon Blumenthal, Vice Affairs | ||
Adam Schechter, President of Global Human Health and Executive VP | ||
Risa LavizzoMourey, Independent Director | ||
Thomas Glocer, Lead Independent Director | ||
Craig Thompson, Independent Director | ||
Cristal Downing, Executive Vice President, Chief Communications, Public Affairs Officer | ||
Jennifer Zachary, Executive Vice President, General Counsel, Corporate Secretary | ||
Arpa Garay, Lead - Human Health Global Marketing | ||
Dalton III, Principal Finance | ||
Christine Seidman, Independent Director | ||
Wendell Weeks, Independent Director | ||
Michael Holston, Executive Vice President Chief Ethics and Compliance Officer | ||
Kathy Warden, Independent Director | ||
Adele Ambrose, Senior Vice President Chief Communications Officer | ||
Joseph Romanelli, IR Contact Officer | ||
Peter Wendell, Independent Director | ||
John Noseworthy, Independent Director | ||
Leslie Brun, Lead Independent Director | ||
Inge Thulin, Independent Director | ||
Pamela Craig, Independent Director | ||
Willie Deese, Executive Vice President and Presidentident - Merck Manufacturing Division | ||
Rita Karachun, Principal Accounting Officer, Sr. VP of Fin. and Global Controller | ||
Dean Li, Executive Vice President and Presidentident, Merck Research Laboratories | ||
Chirfi Guindo, Senior Health | ||
Joerg Koglin, Vice Development | ||
Stephen Mayo, Independent Director | ||
Michael Nally, Executive Vice President, Chief Marketing Officer | ||
Peter Dannenbaum, Vice Relations | ||
Clark Golestani, CIO and Executive VP | ||
Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories | ||
Ashley Watson, Senior Vice President Chief Ethics and Compliance Officer | ||
Carlos Represas, Independent Director | ||
Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health | ||
Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer | ||
Frank Clyburn, Executive Vice President, Chief Commercial Officer | ||
Robert JD, President Chairman |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.009 | ||||
Return On Asset | 0.0264 | ||||
Profit Margin | 0.01 % | ||||
Operating Margin | 0.0008 % | ||||
Current Valuation | 347.78 B | ||||
Shares Outstanding | 2.53 B | ||||
Shares Owned By Insiders | 0.04 % | ||||
Shares Owned By Institutions | 78.59 % | ||||
Number Of Shares Shorted | 19.59 M | ||||
Price To Earning | 18.05 X |
Merck Investors Sentiment
The influence of Merck's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Merck. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Merck's public news can be used to forecast risks associated with an investment in Merck. The trend in average sentiment can be used to explain how an investor holding Merck can time the market purely based on public headlines and social activities around Merck Company. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Merck's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Merck's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Merck's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Merck.
Merck Implied Volatility | 41.87 |
Merck's implied volatility exposes the market's sentiment of Merck Company stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Merck's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Merck stock will not fluctuate a lot when Merck's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Merck in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Merck's short interest history, or implied volatility extrapolated from Merck options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for Merck Stock analysis
When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |
Is Merck's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.453 | Dividend Share 2.92 | Earnings Share 0.14 | Revenue Per Share 23.695 | Quarterly Revenue Growth 0.058 |
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.